Related Experiment Video
Updated: Aug 5, 2025
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Nanoparticles in the New Era of Cardiovascular Therapeutics: Challenges and Opportunities
Pingping Yang1, Jun Ren2,3, Lifang Yang1,4
1Department of Anesthesiology, Xi'an Children Hospital, Xi'an 710032, China.
Insights
Cardiovascular nanomedicine utilizes engineered nanocarriers to improve drug delivery for cardiovascular diseases (CVDs). This innovative approach enhances treatment outcomes for conditions like heart disease and hypertension.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiology
Background:
- Cardiovascular diseases (CVDs) remain a leading global cause of death, with current treatments like medication and surgery having limitations.
- Nanocarriers offer a novel therapeutic strategy by modifying and packaging drugs for targeted delivery within the cardiovascular system.
- Cardiovascular nanomedicine (CVN) is an emerging field with significant potential to address unmet clinical needs in CVD management.
Purpose of the Study:
- To review recent research advances in the application of nanoparticles for managing various cardiovascular diseases.
- To highlight the role of nanocarrier design in optimizing drug delivery and treatment efficacy for CVDs.
- To provide a comprehensive overview of nanoparticles in the context of specific CVDs.
Main Methods:
- Literature review of studies on nanoparticles in cardiovascular nanomedicine.
- Analysis of nanocarrier properties and their impact on drug delivery.
- Summarization of research on nanoparticle applications for specific cardiovascular conditions.
Main Results:
- Nanocarriers, composed of biomaterials or metals, enable targeted delivery of therapeutic agents to cardiovascular tissues, cells, and molecules.
- Advances in nanocarrier design have shown promise in improving drug delivery efficiency and therapeutic outcomes for CVDs.
- Nanoparticle-based strategies are being explored for a wide range of cardiovascular conditions, including heart disease, hypertension, and thrombosis.
Conclusions:
- Cardiovascular nanomedicine represents a promising frontier in treating cardiovascular diseases.
- Optimized nanocarrier design is crucial for enhancing the clinical utility of nanomedicine in cardiology.
- Further research and development in this area hold the potential to significantly improve patient care for cardiovascular conditions.
Abstract:
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. Although a cadre of therapeutic strategies have been made available for CVDs in the clinical setting, predominantly through medication and surgery, these do not fully address the clinical needs of patients with CVD. As a new technique for CVD treatment, nanocarriers are employed to modify and package medications to ease the targeting of tissues, cells and molecules within the cardiovascular system. Nanocarriers are made of biomaterials, metals, or a combination of these materials, with sizes similar to bioactive molecules such as proteins and DNA. Cardiovascular nanomedicine (CVN) has only surfaced in recent years and is still in its infancy. Ample studies have displayed promise for the clinical utility of nanomedicine techniques, courtesy of continued perfection in nanocarrier design to optimize drug delivery and treatment outcomes. Here in this review, we will summarize the research advances in the literature on nanoparticles in the management of CVDs, including ischemic and coronary heart disease (e.g., atherosclerosis, angina pectoris and myocardial infarction), myocardial ischemia-reperfusion injury, aortic aneurysm, myocarditis, hypertension, and pulmonary artery hypertension and thrombosis.
